Details for Patent: 12,156,914

Which drugs does patent 12,156,914 protect, and when does it expire?

Patent 12,156,914 protects AUVELITY and is included in one NDA.

This patent has ten patent family members in seven countries.

Summary for Patent: 12,156,914

Title:	Pharmaceutical compositions comprising bupropion and cysteine
Abstract:	This disclosure relates to pharmaceutical compositions comprising bupropion and cysteine, and pharmaceutical dosage forms comprising bupropion and cysteine. The disclosure also relates to molecular complexes of bupropion and cysteine. These compositions and dosage forms may have improved stability of bupropion.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US18/169,402
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 12,156,914

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes	12,156,914		Y

International Family Members for US Patent 12,156,914

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2023301411
China	118785900
China	121177273
China	122325343
European Patent Office	4547234
Japan	2025521817
South Korea	20250029202